|
"許駿"的相关文件
显示项目 11-60 / 148 (共3页)
1 2 3 > >>
每页显示[10|25|50]项目
| 臺大學術典藏 |
2018-09-10T07:19:44Z |
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival
|
Shen, Y.-C. and Hu, F.-C. and Jeng, Y.-M. and Chang, Y.-T. and Lin, Z.-Z. and Chang, M.-C. and Hsu, C. and Cheng, A.-L.; 沈盈君;胡賦強;鄭永銘;張毓廷;林宗哲;章明珠;許駿;鄭安理; SHEN, YING-CHUN;HU, FU-CHANG;JENG, YUNG-MING;CHANG, YU-TING;LIN, ZONG-ZHE;CHANG, MING-CHU;HSU, CHIUN;CHENG, ANN-LII; YUNG-MING JENG; YU-TING CHANG; ANN-LII CHENG; SHEN, YING-CHUN; HU, FU-CHANG; JENG, YUNG-MING; CHANG, YU-TING; LIN, ZONG-ZHE; CHANG, MING-CHU; HSU, CHIUN; CHENG, ANN-LII |
| 國家衛生研究院 |
2017 |
探討醛酮還原?1B10及其代謝產物參與肝細胞癌上皮細胞間質轉化及抗藥性之角色
|
劉俊揚;許駿;柯博升;郭呈欽;鄭靜枝;詹以吉 |
| 國立臺灣大學 |
2016 |
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression
|
Hsu, Chiun; Lin, Liang-In; Cheng, Yu-Che; Feng, Zi-Rui; Shao, Yu-Yun; Cheng, Ann-Lii; Ou, Da-Liang; 邵幼雲; 林亮音; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2016 |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Yang, Shih-Hung; Kuo, Ting-Chun; Wu, Hsu; Guo, Jhe-Cyuan; Hsu, Chiun; Hsu, Chih-Hung; Tien, Yu-Wen; Yeh, Kun-Huei; Cheng, Ann-Lii; Kuo, Sung-Hsin; 郭頌鑫; 鄭安理; 徐志宏; 許駿; 葉坤輝; 郭哲銓; 田郁文; 郭庭均; 楊士弘 |
| 國立臺灣大學 |
2016 |
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer
|
Chiang, Nai-Jung; Hsu, Chiun; Chen, Jen-Shi; Tsou, Hsiao-Hui; Shen, Ying-Ying; Chao, Yee; Chen, Ming-Huang; Yeh, Ta-Sen; Shan, Yan-Shen; Huang, Shiu-Feng; Chen, Li-Tzong; 許駿 |
| 國立臺灣大學 |
2016 |
Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy
|
Chen, Bang-Bin; Hsu, Chao-Yu; Yu, Chih-Wei; Liang, Po-Chin; Hsu, Chiun; Hsu, Chih-Hung; Cheng, Ann-Lii; Shih, Tiffany Ting-Fang; 許昭禹; 鄭安理; 陳邦斌; 徐志宏; 許駿; 梁博欽; 游治維 |
| 國立臺灣大學 |
2016 |
Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges
|
Lu, Li-Chun; Hsu, Chih-Hung; Hsu, Chiun; Cheng, Ann-Lii; 鄭安理; 徐志宏; 許駿; 呂理駿 |
| 國立臺灣大學 |
2016 |
Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study
|
Melero, I.; Sangro, B.; Yau, T.; Hsu, C.; Kudo, M.; Crocenzi, T.; Kim, T-Y.; Choo, S-P.; Trojan, J.; Meyer, T.; Welling, T. H., III; Yeo, W.; Chopra, A.; Anderson, J.; Dela Cruz, C.; Lang, L.; Neely, J.; El-Khoueiry, A.; 許駿 |
| 國立臺灣大學 |
2016 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
Shao, Y-Y.; Chen, B-B.; Lin, Z-Z.; Hsu, C-H.; Wang, M-J.; Cheng, A-L.; Hsu, C.; 邵幼雲; 林宗哲; 鄭安理; 陳邦斌; 徐志宏; 許駿 |
| 國家衛生研究院 |
2016 |
肝細胞癌中ZNF479所調控之第一型金屬硫蛋白作為抗藥性標的物及抗癌藥物篩選平台之探討與應用
|
劉俊揚;詹以吉;鄭靜枝;許駿;柯博升 |
| 國立臺灣大學 |
2015 |
Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
|
Ou, Da-Liang; Shyue, Song-Kun; Lin, Liang-In; Feng, Zi-Rui; Liou, Jun-Yang; Fan, Hsiang-Hsuan; Lee, Bin-Shyun; Hsu, Chiun; Cheng, Ann-Lii; 林亮音; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2015 |
LONG-TERM OUTCOME OF CHEMOTHERAPY-INDUCED HBV REACTIVATION IN LYMPHOMA PATIENTS WITH RESOLVED HBV INFECTION
|
Yang, H. -C.; Tsou, H. -H.; Chuang, M. -H.; Chen, C. -L.; Liu, T. -W.; Chen, P. -J.; Cheng, A. -L.; Hsu, C.; 鄭安理; 許駿; 陳培哲; 陳祈玲 |
| 國立臺灣大學 |
2015 |
The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia
|
Kuo, Hung-Yang; Lin, Zhong-Zhe; Kuo, Raymond; Shau, Wen-Yi; Lai, Chiu-Lin; Yang, Yen-Yun; Shao, Yu-Yun; Hsu, Chiun; Cheng, Wen-Fan; Cheng, Ann-Lii; Yang, James Chih-Hsin; Lai, Mei-Shu; 郭漢岳; 郭弘揚; 鄭文芳; 楊志新; 邵幼雲; 賴美淑; 林宗哲; 鄭安理; 許駿 |
| 國立臺灣大學 |
2015 |
Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)
|
Hsu, Chiun; Chen, Bang-Bin; Chen, Chien-Hung; Ho, Ming-Chih; Cheng, Jason Chia-Hsien; Kokudo, Norihiro; Murakami, Takamichi; Yeo, Winnie; Seong, Jinsil; Jia, Ji-Dong; Han, Kwan-Hyub; Cheng, Ann-Lii; 鄭安理; 成佳憲; 陳邦斌; 許駿; 陳健弘; 何明志 |
| 國家衛生研究院 |
2015 |
探討第一型金屬硫蛋白異構體在肝細胞癌中之選擇性調控及其可能之治療應用
|
劉俊揚;許駿;柯博升;詹以吉 |
| 國立臺灣大學 |
2014 |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity
|
Kuo, S-H; Yeh, K-H; Chen, L-T; Lin, C-W; Hsu, P-N; Hsu, C.; Wu, M-S; Tzeng, Y-S; Tsai, H-J; Wang, H-P; Cheng, A-L; 林中梧; 郭頌鑫; 鄭安理; 許駿; 葉坤輝; 王秀伯; 吳明賢; 許秉寧 |
| 國立臺灣大學 |
2014 |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma
|
Ou, Da-Liang; Chang, Chun-Jung; Jeng, Yung-Ming; Lin, Yi-Jang; Lin, Zhong-Zhe; Gandhi, Anita K.; Liao, Sheng-Chieh; Huang, Zi-Ming; Hsu, Chiun; Cheng, Ann-Lii; 鄭永銘; 張純榮; 林宗哲; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2014 |
Vertical blockade of the IGFR-PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin
|
Ou, Da-Liang; Lee, Bin-Shyun; Lin, Liang-In; Liou, Jun-Yang; Liao, Sheng-Chieh; Hsu, Chiun; Cheng, Ann-Lii; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2014 |
Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer
|
Shen, Ying-Chun; Li, Chung-Pin; Yen, Chia-Jui; Hsu, Chiun; Lin, Yu-Lin; Lin, Zhong-Zhe; Chen, Li-Tzong; Su, Wu-Chou; Chao, Yee; Yeh, Kun-Huei; Cheng, Ann-Lii; 林宗哲; 林育麟; 鄭安理; 許駿; 葉坤輝 |
| 國立臺灣大學 |
2014 |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao, Hsiang-Fong; Chen, I-Chun; Hsu, Chiun; Chang, Sin-Yuan; Chien, Shu-Fen; Chen, Yee-Chun; Hu, Fu-Chang; Yang, James Chih-Hsin; Cheng, Ann-Lii; Yeh, Kun-Huei; 楊志新; 高祥豐; 陳怡君; 鄭安理; 許駿; 葉坤輝; 陳宜君 |
| 國立臺灣大學 |
2014 |
The impact of diabetes mellitus on early cervical cancer in Asia: A population-based cohort study
|
Kuo, Hung-Yang; Lin, Zhong-Zhe; Kuo, Raymond Nienchen; Shau, Wen-Yi; Lai, Chiu-Lin; Yang, Yen-Yun; Shao, Yu Yun; Hsu, Chiun; Chang, Wen-Fang; Chang, Ann-Lii; Yang, James Chih-Hsin; Lai, Mei-Shu; 楊志新; 邵幼雲; 賴美淑; 鄭安理; 許駿; 賴秋伶 |
| 國立臺灣大學 |
2014 |
Comparison of Characteristics and Transarterial Chemoembolization Outcomes in Patients with Unresectable Hepatocellular Carcinoma and Different Viral Etiologies
|
Chen, Bang-Bin; Shih, I-Lun; Wu, Chih-Horng; Hsu, Chiun; Chen, Chien-Hung; Shih, Tiffany Ting-Fang; Liu, Kao-Lang; Liang, Po-Chin; 吳志宏; 施庭芳; 陳邦斌; 許駿; 施怡倫; 陳健弘; 劉高郎; 梁博欽 |
| 國立臺灣大學 |
2014 |
Chemotherapy-Induced Hepatitis B Reactivation in Lymphoma Patients With Resolved HBV Infection: A Prospective Study
|
Hsu, Chiun; Tsou, Hsiao-Hui; Lin, Shyh-Jer; Wang, Ming-Chung; Yao, Ming; Hwang, Wen-Li; Kao, Woei-Yau; Chiu, Chang-Fang; Lin, Sheng-Fung; Lin, Johnson; Chang, Cheng-Shyong; Tien, Hwei-Fang; Liu, Tsang-Wu; Chen, Pei-Jer; Cheng, Ann-Lii; 姚明; 鄭安理; 許駿; 田蕙芬; 陳培哲 |
| 國立臺灣大學 |
2014 |
H3K9 Histone Methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 Pathway to Suppress Lung Cancer Metastasis
|
Wu, Pei-Chun; Lu, Jeng-Wei; Yang, Jer-Yen; Lin, I-Hsuan; Ou, Da-Liang; Lin, Yu-Hsiang; Chou, Kuan-Hsien; Huang, Wen-Feng; Wang, Wan-Ping; Huang, Yih-Leh; Hsu, Chiun; Lin, Liang-In; Lin, Yueh-Min; Shen, C. -K. James; Tzeng, Tsai-Yu; 林亮音; 許駿; 歐大諒 |
| 國立臺灣大學 |
2014 |
Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan
|
Chang, Yu-Ting; Chang, Ming-Chu; Huang, Kai-Wen; Tung, Chien-Chih; Hsu, Chiun; Wong, Jau-Min; 董建志; 黃凱文; 許駿; 章明珠; 張毓廷 |
| 國立臺灣大學 |
2014 |
Development of GADD45 beta (growth arrest DNA damage-inducible gene 45 beta) agonists for the treatment of hepatocellular carcinoma (HCC)
|
Hsu, Chiun; Ou, Da-Liang; Chen, Kuen-Feng; Lin, Zhong-Zhe; Cheng, Ann-Lii; Shiau, Chung-Wai; 林宗哲; 鄭安理; 許駿; 陳昆鋒; 歐大諒 |
| 國立臺灣大學 |
2014 |
Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma
|
Chang, Ming-Chu; Chen, Chien-Hung; Liang, Ja-Der; Tien, Yu-Wen; Hsu, Chiun; Wong, Jau-Min; Chang, Yu-Ting; 翁昭旼; 許駿; 章明珠; 田郁文; 陳健弘; 張毓廷; 梁嘉德 |
| 國立臺灣大學 |
2014 |
Strategy for Preventing Hepatitis B Reactivation in Patients With Resolved Hepatitis B Virus Infection After Rituximab-Containing Chemotherapy Reply
|
Hsu, Chiun; Chen, Pei-Jer; Cheng, Ann-Lii; 鄭安理; 許駿 |
| 國立臺灣大學 |
2014 |
PREVENTION OF CHEMOTHERAPY-INDUCED HBV-RELATED HEPATITIS FLARE IN LYMPHOMA PATIENTS WITH RESOLVED HBV INFECTION: COST ANALYSIS
|
Tsou, H. -H.; Yang, H. -C.; Chuang, M. -H.; Wu, H. -Y.; Hsu, Y. -T.; Chang, W. -J.; Hsiao, C. -F.; Hsu, C.; 許駿 |
| 國立臺灣大學 |
2013 |
14-3-3 epsilon Overexpression Contributes to Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma
|
Liu, Tzu-An; Jan, Yee-Jee; Ko, Bor-Sheng; Liang, Shu-Man; Chen, Shyh-Chang; Wang, John; Hsu, Chiun; Wu, Yao-Ming; Liou, Jun-Yang; 柯博升; 許駿; 吳耀銘 |
| 國立臺灣大學 |
2013 |
Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients
|
Chen, I. C.; Hsu, C.; Chen, Y. C.; Chien, S. F.; Kao, H. F.; Chang, S. Y.; Hu, F. C.; Yeh, K. H.; 許駿; 葉坤輝; 陳宜君 |
| 國立臺灣大學 |
2013 |
Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression (vol 15, pg 265, 2012)
|
Hsu, Chiun; Shen, Ying-Chun; Cheng, Chia-Chi; Cheng, Ann-Lii; Hu, Fu-Chang; Yeh, Kun-Huei; 鄭安理; 許駿; 葉坤輝 |
| 國立臺灣大學 |
2013 |
Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study
|
Hsu, Chih-Hung; Kang, Yoon Koo; Yang, Tsai-Shen; Shun, Chia-Tung; Shao, Yu-Yun; Su, Wu-Chou; Sandoval-Tan, Jennifer; Chiou, Tzeon-Jye; Jin, Kate; Hsu, Chiun; Cheng, Ann-Lii; 邵幼雲; 鄭安理; 徐志宏; 許駿; 孫家棟 |
| 國立臺灣大學 |
2013 |
Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway
|
Ou, Da-Liang; Lee, Bin-Shyun; Chang, Ya-Chi; Lin, Liang-In; Liou, Jun-Yang; Hsu, Chiun; Cheng, Ann-Lii; 林亮音; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2013 |
The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines
|
Chen, Wei-Wu; Chang, Dwan-Ying; Huang, Shu-Min; Lin, Ching-Hung; Hsu, Chun; Lin, Ming-Hwai; Huang, Chiun-Shen; Lu, Yen-Shen; Cheng, Ann-Lii; 陳偉武; 盧彥伸; 鄭安理; 許駿; 黃俊升; 張端瑩; 林璟宏 |
| 國立臺灣大學 |
2013 |
Radiofrequency Ablation Is Superior to Ethanol Injection in Early-Stage Hepatocellular Carcinoma Irrespective of Tumor Size
|
Lin, Zhong-Zhe; Shau, Wen-Yi; Hsu, Chiun; Shao, Yu-Yun; Yeh, Yi-Chun; Kuo, Raymond Nien-Chen; Hsu, Chih-Hung; Yang, James Chih-Hsin; Cheng, Ann-Lii; Lai, Mei-Shu; 楊志新; 邵幼雲; 賴美淑; 林宗哲; 鄭安理; 徐志宏; 許駿 |
| 國立臺灣大學 |
2013 |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao, Yu-Yun; Liang, Po-Chin; Wu, Yao-Ming; Huang, Chun-Chieh; Huang, Kai-Wen; Cheng, Jason C.; Hsu, Chih-Hung; Hsu, Chiun; Cheng, Ann-Lii; Lin, Zhong-Zhe; 邵幼雲; 林宗哲; 鄭安理; 成佳憲; 黃凱文; 徐志宏; 許駿; 梁博欽; 吳耀銘 |
| 國立臺灣大學 |
2013 |
Survival of patients receiving radiofrequency ablation or ethanol injection for early-stage hepatocellular carcinoma.
|
Lin, Zhong-Zhe; Shau, Wen-Yi; Shao, Yu Yun; Yeh, Yi-Chun; Kuo, Raymond Nien-Chen; Hsu, Chiun; Hsu, Chih-Hung; Cheng, Ann-Lii; Lai, Mei-Shu; 邵幼雲; 賴美淑; 林宗哲; 鄭安理; 徐志宏; 許駿; 郭年真 |
| 國立臺灣大學 |
2013 |
Potential synergistic antitumor activity between sorafenib and lenalidomide in an orthotopic murine liver cancer model.
|
Chang, Chun-Jung; Ou, Da-Liang; Lin, Yi-Jang; Cheng, Ann-Lii; Hsu, Chiun; 張純榮; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2013 |
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
|
Shen, Y-C; Ou, D-L; Hsu, C.; Lin, K-L; Chang, C-Y; Lin, C-Y; Liu, S-H; Cheng, A-L; 劉興華; 鄭安理; 許駿; 歐大諒; 林靖愉 |
| 國立臺灣大學 |
2012 |
PHASE II STUDY OF CONCOMITANT THALIDOMIDE DURING RADIOTHERAPY FOR HEPATOCELLULAR CARCINOMA
|
Ch' ang, Hui-Ju; Hsu, Chiun; Chen, Chien-Hung; Chang, Ya-Hui; Chang, Jeffrey S.; Chen, Li-Tzong; 許駿; 陳健弘 |
| 國立臺灣大學 |
2012 |
Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma
|
Shao, Yu-Yun; Lin, Zhong-Zhe; Hsu, Chiun; Lee, Kuan-Der; Hsiao, Chi-Huang; Lu, Yen-Shen; Huang, Chien-Chung; Shen, Yin-Chun; Hsu, Chih-Hung; Cheng, Ann-Lii; 盧彥伸; 邵幼雲; 林宗哲; 鄭安理; 徐志宏; 許駿 |
| 國立臺灣大學 |
2012 |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Hsu, Chiun; Yang, Tsai-Sheng; Huo, Teh-Ia; Hsieh, Ruey-Kuen; Yu, Chih-Wei; Hwang, Wei-Shou; Hsieh, Tsai-Yuan; Huang, Wen-Tsung; Chao, Yee; Meng, Robin; Cheng, Ann-Lii; 鄭安理; 許駿; 游治維 |
| 國立臺灣大學 |
2012 |
A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression
|
Shen, Ying-Chun; Hsu, Chiun; Cheng, Chia-Chi; Hu, Fu-Chang; Cheng, Ann-Lii; 鄭安理; 許駿; 胡賦強 |
| 國立臺灣大學 |
2012 |
Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy
|
Lin, Zhong-Zhe; Hsu, Chiun; Hu, Fu-Chang; Shao, Yu-Yun; Chang, Dwan-Ying; Yang, Chih-Hsin; Hong, Ruey-Long; Hsu, Chih-Hung; Cheng, Ann-Lii; 楊志新; 邵幼雲; 林宗哲; 鄭安理; 徐志宏; 洪瑞隆; 許駿; 胡賦強; 張端瑩 |
| 國立臺灣大學 |
2012 |
Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression
|
Hsu, Chiun; Shen, Ying-Chun; Cheng, Chia-Chi; Cheng, Ann-Lii; Hu, Fu-Chang; Yeh, Kun-Huei; 鄭安理; 許駿; 葉坤輝 |
| 國立臺灣大學 |
2012 |
Metastasectomy of Krukenberg Tumors May Be Associated with Survival Benefits in Patients with Metastatic Gastric Cancer
|
Lu, Li-Chun; Shao, Yu-Yun; Hsu, Chih-Hung; Hsu, Chun; Cheng, Wen-Fang; Lin, Yu-Lin; Cheng, Ann-Lii; Yeh, Kun-Huei; 鄭文芳; 邵幼雲; 林育麟; 鄭安理; 徐志宏; 許駿; 葉坤輝; 呂理駿 |
| 國立臺灣大學 |
2012 |
EXPLORING THE ANTI-TUMOR EFFICACY OF COMBINATION THERAPY WITH INHIBITORS TARGETING THE INSULIN-LIKE GROWTH FACTOR (IGF) AND PI3K/AKT/MTOR SIGNALING PATHWAYS FOR HEPATOCELLULAR CARCINOMA (HCC)
|
Ou, D. -L.; Hsu, C.; Lee, B. -S.; Chang, Y. -C.; Cheng, Y. -C.; Cheng, A. -L.; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2012 |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao, Y-Y; Lu, L-C; Lin, Z-Z; Hsu, C.; Shen, Y-C; Hsu, C-H; Cheng, A-L; 邵幼雲; 林宗哲; 鄭安理; 徐志宏; 許駿; 呂理駿 |
| 國立臺灣大學 |
2012 |
THE ROLES OF GROWTH ARREST DNA DAMAGE-INDUCIBLE GENE 45 Gamma (GADD45 Gamma) EXPRESSION IN SORAFENIB-INDUCED APOPTOSIS IN HEPATOCELLULAR CARCINOMA (HCC) CELLS
|
Hsu, C.; Ou, D. -L.; Shiau, C. -W.; Fan, H. -H.; Liao, S. -C.; Lin, Y. -Y.; Hsu, C. -H.; Cheng, A. -L.; 林育誼; 鄭安理; 徐志宏; 許駿; 歐大諒 |
Showing items 11-60 of 148 (3 Page(s) Totally)
1 2 3 > >>
View [10|25|50] records per page
|
